Interactive Financial Charts Not Available

Regencell Bioscience (RGC) | Financial Analysis & Statements

Regencell Bioscience Holdings Ltd. | Mid-cap | Healthcare

$16.15

2.02%

| Regencell Bioscience Stock Comparison:

Regencell Bioscience vs Haleon Plc - ADR Regencell Bioscience vs United Therapeutics Regencell Bioscience vs Elanco Animal Health Regencell Bioscience vs Alkermes plc Regencell Bioscience vs Prestige Consumer Regencell Bioscience vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 8.4M

Total Liabilities 219.5K

Shareholders Equity 8.2M

Debt to Equity 0.03

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Regencell Bioscience Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	0	0	0	0	0
Cost of Goods Sold i	-	-	-	-	-
Gross Profit i	-	-	-	-	-
Gross Margin % i	0.0%	0.0%	0.0%	0.0%	0.0%
Operating Expenses
Research & Development i	1.1M	1.6M	2.5M	438.3K	386.2K
Selling, General & Administrative i	3.7M	4.7M	5.1M	943.0K	426.1K
Other Operating Expenses i	-	-	-	-	-
Total Operating Expenses i	4.7M	6.3M	7.6M	1.4M	812.4K
Operating Income i	-4.7M	-6.3M	-7.6M	-1.4M	-812.4K
Operating Margin % i	0.0%	0.0%	0.0%	0.0%	0.0%
Non-Operating Items
Interest Income i	-	-	-	-	-
Interest Expense i	-	-	-	-	-
Other Non-Operating Income	373.5K	211.3K	23.2K	34.6K	-
Pre-tax Income i	-4.4M	-6.1M	-7.6M	-1.3M	-812.4K
Income Tax i	0	0	0	0	0
Effective Tax Rate % i	0.0%	0.0%	0.0%	0.0%	0.0%
Net Income i	-4.4M	-6.1M	-7.6M	-1.3M	-812.4K
Net Margin % i	0.0%	0.0%	0.0%	0.0%	0.0%
Key Metrics
EBITDA i	-4.0M	-5.5M	-7.0M	-1.4M	-802.9K
EPS (Basic) i	$-0.01	$-0.01	$-0.02	$-0.11	$-0.06
EPS (Diluted) i	$-0.01	$-0.01	$-0.02	$-0.11	$-0.06
Basic Shares Outstanding i	494488908	494488908	486616866	12642105	12642105
Diluted Shares Outstanding i	494488908	494488908	486616866	12642105	12642105

Income Statement Trend

Regencell Bioscience Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	3.0M	1.6M	6.4M	59.4K	387.0K
Short-term Investments i	5.0M	10.0M	10.0M	0	-
Accounts Receivable i	-	-	-	-	-
Inventory i	-	-	-	-	-
Other Current Assets	-	-	-	-	-
Total Current Assets i	8.1M	11.6M	16.4M	66.8K	387.0K
Non-Current Assets
Property, Plant & Equipment i	84.8K	451.1K	747.4K	0	0
Goodwill i	-	-	-	-	-
Intangible Assets i	-	-	-	-	-
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	-	-	0	172.3K	0
Total Non-Current Assets i	324.2K	1.0M	1.6M	273.3K	127.0K
Total Assets i	8.4M	12.6M	18.0M	340.1K	514.0K
Liabilities
Current Liabilities
Accounts Payable i	-	-	-	-	-
Short-term Debt i	59.8K	438.3K	411.0K	3.7M	3.1M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities i	193.6K	606.9K	577.8K	4.3M	3.2M
Non-Current Liabilities
Long-term Debt i	25.9K	25.4K	360.3K	0	-
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	-	-	-	-	-
Total Non-Current Liabilities i	25.9K	25.4K	360.3K	0	0
Total Liabilities i	219.5K	632.3K	938.0K	4.3M	3.2M
Equity
Common Stock i	130	130	130	100	100
Retained Earnings i	-21.6M	-17.3M	-11.4M	-4.0M	-2.7M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	8.2M	12.0M	17.1M	-4.0M	-2.7M
Key Metrics
Total Debt i	85.7K	463.7K	771.3K	3.7M	3.1M
Working Capital i	7.9M	11.0M	15.9M	-4.3M	-2.8M

Balance Sheet Composition

Regencell Bioscience Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	-4.4M	-6.1M	-7.6M	-1.3M	-812.4K
Depreciation & Amortization i	745.6K	769.7K	604.4K	26.5K	9.5K
Stock-Based Compensation i	449.3K	922.6K	2.8M	0	0
Working Capital Changes i	-465.1K	-487.7K	-430.4K	0	0
Operating Cash Flow i	-3.9M	-4.9M	-4.7M	-1.3M	-802.9K
Investing Activities
Capital Expenditures i	-5.4K	-26.4K	-780.9K	0	-117.8K
Acquisitions i	-	-	-	-	-
Investment Purchases i	-5.0M	-10.0M	-10.0M	0	0
Investment Sales i	10.2M	10.1M	0	0	-
Investing Cash Flow i	5.2M	59.0K	-10.8M	0	-117.8K
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	-	-	-	-	-
Debt Repayment i	-	-	-	-	-
Financing Cash Flow i	102.3K	134.9K	22.4M	439.7K	988.1K
Free Cash Flow i	-4.0M	-5.0M	-6.0M	-767.3K	-844.4K
Net Change in Cash i	1.5M	-4.7M	7.0M	-880.5K	67.4K

Cash Flow Trend

Regencell Bioscience Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -1,779.13

Price to Book 1,121.43

Profitability Ratios

Profit Margin 0.00%

Operating Margin 0.00%

Return on Equity -47.77%

Return on Assets -30.65%

Financial Health

Debt to Equity 0.00

Beta 2.15

Per Share Data

EPS (TTM) $-0.01

Book Value per Share $0.01

Revenue per Share $0.00

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
rgc	7.6B	-1,779.13	1,121.43	-47.77%	0.00%	0.00
Haleon Plc - ADR	41.7B	19.93	5.08	9.38%	13.81%	53.41
United Therapeutics	19.3B	16.92	2.68	19.30%	40.36%	0.00
Elanco Animal Health	9.7B	22.28	1.44	6.83%	9.68%	62.13
Alkermes plc	5.3B	13.50	3.11	23.94%	23.15%	4.47
Prestige Consumer	3.8B	17.92	2.07	12.30%	18.86%	56.91

Financial data is updated regularly. All figures are in the company's reporting currency.